CLA After 50: Benefits & Safety
CLA (conjugated linoleic acid) is a group of naturally occurring fatty acid isomers found primarily in meat and dairy products from ruminant animals. It has been studied extensively as a body composition supplement — particularly for its proposed ability to reduce body fat and preserve lean mass. As muscle loss (sarcopenia) and body fat redistribution accelerate after 50, interest in CLA for seniors has grown among older adults looking for evidence-based support beyond diet and exercise alone.
Age-Related Need: Why CLA May Be Relevant After 50
After 50, several converging processes challenge body composition:
- Sarcopenia — the progressive loss of skeletal muscle mass — begins in earnest around 50 and accelerates in the decade after 60.
- Fat redistribution — even at stable body weight, fat tends to shift from peripheral to central (visceral) depots with age.
- Reduced anabolic response to protein — older muscles are less sensitive to the muscle-building stimulus from protein, meaning higher protein intakes and other anabolic strategies become relevant.
CLA's proposed mechanisms — inhibiting fat cell growth (adipogenesis), increasing fat oxidation, and potentially supporting muscle protein synthesis — address these challenges in principle, though the evidence in older adults specifically requires careful evaluation.
Absorption Changes After 50
CLA is a fatty acid and is absorbed as part of the dietary fat digestion process. Absorption depends on adequate bile salt secretion and pancreatic lipase activity — both of which can decline modestly with age. However, for supplemental CLA in softgel or oil form, absorption is generally efficient and age-related differences are not clinically significant at typical supplemental doses.
The two main bioactive isomers in supplemental CLA are c9,t11-CLA (also found in dairy) and t10,c12-CLA. Most research suggests that the t10,c12 isomer is primarily responsible for body fat reduction effects, while c9,t11 may be more relevant to other metabolic effects. Commercial CLA supplements typically provide a roughly equal mixture.
Dose, Safety, and Evidence
A meta-analysis of RCTs found that CLA supplementation was associated with a small but statistically significant reduction in body fat mass in humans — with the reduction averaging around 0.1 kg per week of supplementation relative to placebo (Whigham et al., 2007). This is a modest absolute effect.
The doses used in clinical trials have typically ranged from 3.0 to 6.4 g/day of CLA. Below 3 g/day, effects on body composition appear minimal.
Products available at maxfit.ee include DY CLA Softgel Capsules, OstroVit CLA 1000 150caps, and OstroVit CLA 1000 90caps. For a combination approach, OstroVit CLA + Green Tea + L-carnitine 90 caps pairs CLA with green tea extract and L-carnitine — ingredients that have been used together in body composition research. Browse the CLA category at maxfit.ee.
Safety considerations for older adults:
- Insulin sensitivity: The t10,c12 isomer has been associated with modest worsening of insulin sensitivity in some trials, which is particularly relevant for older adults who already have reduced insulin sensitivity or prediabetes (Smedman & Vessby, 2001). This is the most important safety consideration for this population.
- Liver enzymes: Some longer-term studies have noted mild increases in liver enzymes (ALT/AST) at higher doses, though values typically remained within normal ranges.
- Lipid profile: Effects on LDL and HDL cholesterol are mixed across studies and are generally modest at typical doses.
- Gastrointestinal: Nausea and loose stools are the most common adverse effects, usually mild and dose-dependent. Taking CLA with food reduces this risk.
Interactions with Medication
- Anticoagulants: CLA has mild effects on platelet aggregation; monitoring is advisable if combined with warfarin or aspirin.
- Diabetes medications: Given CLA's potential modest effects on insulin sensitivity, blood glucose monitoring is prudent for those on hypoglycaemic agents.
- Statins and lipid-lowering drugs: The mixed effects on lipid profiles mean CLA's interaction with statin therapy is not clearly defined — discuss with a physician if on statin medication.
When to Supplement
CLA supplementation after 50 is most rational when:
- Modest fat mass reduction is a specific goal alongside diet and resistance training (not as a standalone intervention)
- Insulin sensitivity is normal or only borderline impaired
- Adequate protein intake and regular resistance training are already in place, and CLA is being considered as a marginal additional tool
For older adults with impaired insulin sensitivity, prediabetes, or type 2 diabetes, the risk-benefit calculation for CLA warrants a conversation with a physician given the t10,c12 insulin sensitivity concern.
The evidence for CLA preserving lean mass in older adults specifically is less robust than in younger populations; most of the strongest body composition trials were conducted in younger or middle-aged adults.
FAQ
Does CLA cause fat loss on its own?
Not meaningfully. The small effects documented in trials occurred alongside diet and exercise; CLA is a marginal adjunct at best, not a standalone fat-loss agent. The absolute changes in body fat from CLA trials are small.
Is CLA safe for older adults with blood sugar concerns?
The t10,c12 CLA isomer has been associated with modest reductions in insulin sensitivity in some studies. Older adults with borderline or impaired blood sugar regulation should discuss this with their doctor before supplementing.
How long should I take CLA to assess its effects?
Most body composition changes in CLA trials became apparent over 12 weeks or longer. Short supplementation periods of a few weeks are unlikely to be informative.
References
Whigham, L. D., Watras, A. C., & Schoeller, D. A. (2007). Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. American Journal of Clinical Nutrition, 85(5), 1203-1211. https://pubmed.ncbi.nlm.nih.gov/17490954/
Smedman, A., & Vessby, B. (2001). Conjugated linoleic acid supplementation in humans — metabolic effects. Lipids, 36(8), 773-781. https://pubmed.ncbi.nlm.nih.gov/11592727/
Benito, P., Nelson, G. J., Kelley, D. S., Bartolini, G., Schmidt, P. C., & Simon, V. (2001). The effect of conjugated linoleic acid on plasma lipoproteins and body composition in humans. Lipids, 36(3), 229-236. https://pubmed.ncbi.nlm.nih.gov/11337977/
